US · LMAT
LeMaitre Vascular, Inc.
- Sector
- Healthcare · Medical - Instruments & Supplies
- Headquarters
- Burlington, MA 01803
- Website
- lemaitre.com
Price · as of 2024-12-31
$112.04
Market cap 2.45B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $58.55 | -47.74% |
| Intrinsic Value(DCF) | $53.51 | -52.24% |
| Graham-Dodd Method(GD) | $12.29 | -89.03% |
| Graham Formula(GF) | $41.46 | -62.99% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $5.78 | $31.86 | $0.90 | $4.51 | $6.88 |
| 2011 | $4.75 | $71.40 | $0.53 | $2.09 | $1.50 |
| 2012 | $5.20 | $30.89 | $0.84 | $1.92 | $1.12 |
| 2013 | $7.11 | $33.02 | $0.66 | $1.96 | $4.46 |
| 2014 | $6.97 | $31.62 | $0.88 | $2.16 | $4.21 |
| 2015 | $13.83 | $37.57 | $3.04 | $3.16 | $7.81 |
| 2016 | $20.67 | $42.02 | $8.56 | $3.63 | $12.22 |
| 2017 | $34.18 | $52.27 | $16.02 | $5.75 | $18.80 |
| 2018 | $27.74 | $48.08 | $12.31 | $6.87 | $14.80 |
| 2019 | $26.39 | $45.53 | $0.74 | $4.89 | $16.88 |
| 2020 | $45.91 | $49.14 | $0.06 | $4.81 | $18.95 |
| 2021 | $40.81 | $44.70 | $4.58 | $8.63 | $33.94 |
| 2022 | $46.67 | $49.39 | $0.00 | $6.40 | $11.77 |
| 2023 | $66.05 | $52.16 | $12.77 | $8.81 | $36.42 |
| 2024 | $80.62 | $58.55 | $28.13 | $12.29 | $41.46 |
AI valuation
Our deep-learning model estimates LeMaitre Vascular, Inc.'s (LMAT) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $58.55
- Current price
- $112.04
- AI upside
- -47.74%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$53.51
-52.24% upside
Graham-Dodd
$12.29
-89.03% upside
Graham Formula
$41.46
-62.99% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| LMAT | LeMaitre Vascular, Inc. | $112.04 | 2.45B | -48% | -52% | -89% | -63% | 41.10 | 5.37 | 8.23 | 25.41 | 93.35 | 7.69 | 68.63% | 23.77% | 20.03% | 13.87% | 18.60% | 9.80% | 0.55 | 254.91 | 13.14 | 10.77 | 2.40 | 4403.00% | 1363.00% | 2603.00% | 2.05% | 1.44 | 17.08% | 0.79% | 32.60% | 0.79% | 32.46 | 45.64 | 7.71 | 6.95 |
| ACHC | Acadia Healthcare Company… | $23.44 | 2.12B | -60% | -60% | — | — | -1.95 | 1.09 | 0.64 | -6.28 | — | 3.82 | 17.61% | 11.71% | -33.29% | -43.48% | 8.13% | -19.02% | 1.36 | 2.79 | 1.55 | 1.09 | -3.40 | -53741.00% | 504.00% | -2154.00% | -20.69% | 0.25 | -9.22% | 0.00% | 0.00% | 2.35% | 11.95 | -10.54 | 1.40 | 1.08 |
| ATRC | AtriCure, Inc. | $31.26 | 1.56B | +49% | -32% | -90% | — | -129.01 | 3.00 | 2.76 | 86.02 | — | 7.06 | 74.41% | -0.64% | -2.14% | -2.40% | -0.83% | -1.81% | 0.18 | -0.59 | 3.96 | 2.87 | -4.89 | -7474.00% | 1488.00% | -52900.00% | 3.27% | 0.70 | 11.67% | 0.00% | 0.00% | 3.01% | -405.42 | 28.94 | 2.61 | 5.82 |
| AVAH | Aveanna Healthcare Holdin… | $7.36 | 1.54B | — | +111% | — | — | -67.95 | -6.08 | 0.37 | 11.53 | — | -0.59 | 31.39% | 6.90% | -0.54% | — | — | — | -12.30 | 0.89 | 0.98 | 0.90 | 7.57 | — | — | — | 3.54% | 0.08 | — | 0.00% | 0.00% | 0.00% | 15.45 | 82.09 | 1.07 | 0.57 |
| HAE | Haemonetics Corporation | $63.32 | 2.96B | -0% | -52% | -67% | -37% | 21.15 | 4.32 | 2.61 | 12.54 | 47.48 | -14.83 | 57.21% | 16.30% | 12.32% | 18.83% | 10.54% | 7.22% | 1.49 | 22.76 | 1.62 | 0.88 | 2.58 | 4454.00% | 395.00% | 2338.00% | 4.02% | 0.31 | 8.56% | 0.00% | 0.00% | 6.34% | 20.13 | 31.34 | 3.28 | 2.54 |
| INSP | Inspire Medical Systems, … | $64.51 | 1.87B | +102% | +157% | -20% | +62% | 13.09 | 2.44 | 2.09 | 25.07 | 7.29 | 2.44 | 85.39% | 5.59% | 15.95% | 19.77% | 13.05% | 16.95% | 0.04 | 371.93 | 6.08 | 4.46 | -1.12 | 17943.00% | 1360.00% | -1388.00% | 4.12% | 1.22 | 20.10% | 0.00% | 0.00% | 9.20% | 31.94 | 20.74 | 1.78 | 10.66 |
| PAHC | Phibro Animal Health Corp… | $54.59 | 2.21B | +18% | +113% | -92% | -25% | 32.91 | 5.56 | 1.23 | 15.48 | 1.75 | 8.38 | 30.85% | 8.52% | 3.72% | 17.80% | 9.58% | 4.12% | 2.67 | 3.32 | 2.76 | 1.04 | 4.72 | 188333.00% | 2737.00% | -976.00% | 2.63% | 0.27 | 5.11% | 1.22% | 40.30% | 1.22% | 20.57 | 54.33 | 1.75 | 2.84 |
| PRCT | PROCEPT BioRobotics Corpo… | $22.69 | 1.27B | +83% | +106% | — | — | -15.10 | 3.94 | 4.69 | -15.09 | — | 3.95 | 63.70% | -33.71% | -31.02% | -24.89% | -74.26% | -18.34% | 0.14 | -11.69 | 6.85 | 5.62 | 2.93 | -171.00% | 3722.00% | -4370.00% | -4.04% | -0.74 | -41.71% | 0.00% | 0.00% | 0.44% | -11.64 | -20.71 | 3.92 | 5.16 |
| QDEL | QuidelOrtho Corporation | $22.74 | 1.54B | -6% | -60% | — | — | -1.35 | 0.80 | 0.56 | -8.47 | — | -2.38 | 46.67% | -33.67% | -41.45% | -46.15% | -18.22% | -18.56% | 1.46 | -5.18 | 1.50 | 0.64 | -5.40 | -4535.00% | -189.00% | -2596.00% | -5.42% | 0.11 | -1.65% | 0.00% | 0.00% | 0.00% | -4.50 | -49.82 | 1.51 | 0.29 |
| TWST | Twist Bioscience Corporat… | $46.92 | 2.88B | -25% | -66% | -100% | — | -24.87 | 4.08 | 5.13 | -35.25 | — | 5.12 | 50.72% | -36.18% | -20.63% | -16.43% | -41.34% | -12.37% | 0.29 | — | 3.64 | 3.17 | 0.88 | -6389.00% | 2032.00% | 934.00% | -3.92% | -0.52 | -22.95% | 0.00% | 0.00% | 0.00% | -13.48 | -24.28 | 4.88 | 4.32 |
About LeMaitre Vascular, Inc.
LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular and cardiac patches, which are used for closure of vessels after surgical intervention; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
- CEO
- George W. LeMaitre
- Employees
- 651
- Beta
- 0.70
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($53.51 ÷ $112.04) − 1 = -52.24% (DCF, example).